# [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

> **NCT07020806** · PHASE1 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Lobular Breast Carcinoma

## Interventions

- **DRUG:** [68Ga]Ga DOTA-5G

## Key facts

- **NCT ID:** NCT07020806
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020806, "[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07020806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*